

Best of SABCs® 2025 Bulgaria

Highlights from the San Antonio Breast Cancer Symposium® 2025

13–14 February 2026

SCIENTIFIC PROGRAM

Friday, 13 February 2026

11:00 – 18:00 Registration

14:00 – 14:05 Official opening

Assoc. Prof. Assia Konsoulova, MD, PhD

14:05 – 14:40

The Patient Voice: Treatment de-escalation and personalization – mutual adaptation of physicians and patients

Gergana Bogdanova, Stanimir Kacheshmarov, MD; Assoc. Prof. Assia Konsoulova, MD, PhD

14:45 – 15:30 SABCs® 2025 Module 1

AI-assisted screening and risk prediction in breast cancer

Bozhidar Iliev, MD

GRADE-formatted panel discussion

Moderator: Lyubomir Balabanski, MD, DSc

15:35 – 16:20

Industry-supported symposium (MSD)

Multidisciplinary approach to the treatment of triple-negative breast cancer

Assoc. Prof. Assia Konsoulova, MD, PhD

Petya Balikova, MD

Valentin Ivanov, MD

16:20 – 16:45 Coffee Break

16:45 – 17:30 SABCs® 2025 Module 2

Quality of life and survivorship in breast cancer patients

Petya Balikova, MD

GRADE-formatted panel discussion

Moderator: Bozhidar Iliev, MD

17:35 – 18:20

Industry-supported symposium (Novartis)

Moderator: Assoc. Prof. Dimitar Kalev, MD, PhD

What new did the 5-year data from the NATALEE study prove?

Nadejda Miteva, MD

Challenges in lobular carcinoma and long-term effectiveness of *Ribociclib*

Radoslav Mangaldjiev, MD

18:25 – 18:50

Industry-supported symposium (Pfizer)

Real-world PFS2 and tumor response by CDK4/6 in patients with HR+/HER2 metastatic breast cancer and other highlights from SABCS 2025

Vasil Popov, MD

19:00 Dinner

Saturday, 14 February 2026

08:00 – 17:30 Registration

09:00 – 09:45 SABCS® 2025 Module 3

Biomarkers in breast cancer: certainty of evidence for predictive versus prognostic utility

Lyubomir Balabanski, MD, DSc

GRADE-formatted panel discussion

Moderator: *Assoc. Prof. Assia Konsoulova, MD, PhD*

09:50 – 10:20 SABCS® 2025 Module 4

Pathological tools for prediction of treatment response

Fyodor Odzhakov, MD, PhD

GRADE-formatted panel discussion

Moderator: *Assoc. Prof. Svitlana Bachurska, MD, PhD*

10:20 – 10:45 Coffee Break

10:45 – 11:15 SABCS® 2025 Module 5

Magnetic resonance imaging (MRI) in breast cancer: indications and strategies. mPERCIST criteria in metastatic bone disease

Viktor Yordanov, MD; Assoc. Prof. Valeria Hadzhiyska, MD, PhD

GRADE-formatted panel discussion

Moderator: *Assoc. Prof. Valeria Hadzhiyska, MD, PhD*

11:20 – 11:45

Industry-Supported Symposium (Eli Lilly)

Verzenios – stable over time and proven to reduce the risk of relapse after 2 years of therapy in HR+/HER2- early breast cancer with lymph node involvement

Treatment of HR+/HER2- early breast cancer with lymph node involvement – data from real practice

Melek Musin

Patients with HR+/HER2- metastatic breast cancer and high risk of progression – final data from the Monarch 2 and Monarch 3 studies

Yavor Hinov, MD

11:50 – 12:15

Industry-Supported Symposium (Roche)

One for all or all for one

What is the future of HER2+ mBC

Petya Balikova, MD

12:20 – 12:45

Симпозиум, подкрепен от индустрията (Swixx)

Sacituzumab govitecan: modern interpretation of data in the treatment of mTNBC and HR+/HER2- breast cancer

Assoc. Prof. Assia Konsoulova, MD, PhD

12:45 – 13:30 Lunch

13:30 – 14:15

SABCS® 2025 Module 6

Surgical minimalism in breast cancer: defining the limits

Slavyana Usheva, MD

GRADE-formatted panel discussion

Moderator: Valentin Ivanov, MD

14:20 – 14:50 SABCS® 2025 Module 7

De-escalation strategies in radiation therapy for breast cancer

Doroteya Ivanova, MD

GRADE-formatted panel discussion

Moderator: Assoc. Prof. Veselin Popov, MD, PhD

14:55 – 15:40

Industry-Supported Symposium (AstraZeneca)

Therapies that are changing the treatment approach for metastatic HR+ breast cancer

Assoc. Prof. Assia Konsoulova, MD, PhD

Assoc. Prof. Dimitar Kalev, MD, PhD

15:45 – 16:30 SABCS® 2025 Module 8

Systemic therapy in Early Breast Cancer

Assoc. Prof. Assia Konsoulova, MD, PhD; Yavor Hinov, MD

GRADE-formatted panel discussion

Moderator: Assoc. Prof. Assia Konsoulova, MD, PhD

16:30 – 16:45 Coffee Break

16:45 – 17:30 SABCS® 2025 Module 9

Metastatic luminal HER2-negative breast cancer

Dimo Manov, MD

GRADE-formatted panel discussion

Moderator: Assoc. Prof. Assia Konsoulova, MD, PhD

17:35 – 18:20 SABCS® 2025 Module 10

Metastatic HER2-positive and triple-negative breast cancer

Teodora Karanikolova, MD

GRADE-formatted panel discussion

Moderator: Dimo Manov, MD

18:25 – 19:25

SABCS® 2025: practice-changing evidence from Monday onward

Expert position statement of the Bulgarian Joint Cancer Network (BJCN)

Assoc. Prof. Assia Konsoulova, MD, PhD

19:25 – 19:30 Official Closing

Assoc. Prof. Assia Konsoulova, MD, PhD

20:00 Dinner